Inhibitory Metabolic Drug Interactions with Newer Psychotropic Drugs: Inclusion in Package Inserts and Influences of Concurrence in Drug Interaction Screening Software

Abstract

Spanish

French

Background:

Food and Drug Administration (FDA) regulations mandate that package inserts (Pls) include observed or predicted clinically significant drug-drug interactions (DDIs), as well as the results of pharmacokinetic studies that establish the absence of effect.

Objective:

To quantify how frequently observed metabolic inhibition DDIs affecting US-marketed psychotropics are present in FDA-approved Pls and what influence the source of DDI information has on agreement between 3 DDI screening programs.

Methods:

The scientific literature and Pls were reviewed to determine all drug pairs for which there was rigorous evidence of a metabolic inhibition interaction or noninteraction. The DDIs were tabulated noting the source of evidence and the strength of agreement over chance. Descriptive statistics were used to examine the influence of source of DDI information on agreement among 3 DDI screening tools. Logistic regression was used to assess the influence of drug class, indication, generic status, regulatory approval date, and magnitude of effect on agreement between the literature and PI as well as agreement among the DDI screening tools.

Results:

Thirty percent (13/44) of the metabolic inhibition DDIs affecting newer psychotropics were not mentioned in Pls. Drug class, indication, regulatory approval date, generic status, or magnitude of effect did not appear to be associated with more complete DDI information in Pls. DDIs found exclusively in Pls were 3.25 times more likely to be agreed upon by all 3 DDI screening tools than were those found exclusively in the literature. Generic status was inversely associated with agreement among the DDI screening tools (odds ratio 0.11; 95% CI 0.01 to 0.89).

Conclusions:

The presence in Pls of DDI information for newer psychotropics appears to have a strong influence on agreement among DDI screening tools. Users of DDI screening software should consult more than 1 source when considering interactions involving generic psychotropics.

Keywords

drug information services drug interactions drug labeling psychotropic

Get full access to this article

View all access options for this article.

References

Dal-RÉ

, Pedromingo

, Garci'a-Losa

, Lahuerta

, Ortega

. Are results from pharmaceutical-company-sponsored studies available to the public? Eur J Clin Pharmacol 2010; 66:1081–9. doi: 10.1007/s00228-010-0898-y

Hines

, Ceron-Cabrera

, Romero

. Evaluation of warfarin drug interaction listings in US product information for warfarin and interacting drugs. Clin Ther 2011; 33:36–45.

Marroum

, Gobbura

. The product label: how pharmacokinetics and pharmacodynamics reach the prescriber. Clin Pharmacokinet 2002; 41:161–9. doi: 10.1016/j.clinthera.2011.01.021

Steinmetz

, Coley

, Pollock

. Assessment of geriatric information on the drug label for commonly prescribed drugs in older people. J Am Geriatr Soc 2005; 53:891–4. doi: 10.1111/j.1532–5415.2005.53273.x

Tulner

, Frankfort

, Gijsen

GJPT

. Drug-drug interactions in a geriatric outpatient cohort: prevalence and relevance. Drugs Aging 2008; 25:343–55. doi: 10.2165/00002512-200825040-00007

Gurwitz

, Field

, Judge

. The incidence of adverse drug events in two large academic long-term care facilities. Am J Med 2005; 118:251–8. doi: 10.1016/j.amjmed.2004.09.018

Juurlink

, Mamdani

, Kopp

, Laupacis

, Redelmeier

. Drug-drug interactions among elderly patients hospitalized for drug toxicity. JAMA 2003; 289:1652–8. doi: 10.1001/jama.289.13.1652

Hamilton

, Briceland

, Andritz

. Frequency of hospitalization after exposure to known drug-drug interactions in a Medicaid population. Pharmacotherapy 1998; 18:1112–20.

Code of Federal Regulations Title 21. Washington DC: Food and Drug Administration, 2010. http://wwwaccessdata.fda.gov/scripts/cdrh/cfdocs/cfcfr/CFRSearch.cfm?fr=201.57 (accessed 7 Jun 2011).

10.

Boyce

, Handler

, Karp

, Hanlon

. Age-related changes in antidepressant pharmacokinetics and potential drug-drug interactions: a comparison of evidence-based literature and package insert information. Am J Geriatr Pharmacother 2012; 10:139–50. doi: 10.1016/j.amjopharm.2012.01.001

11.

Spina

, de Leon

. Metabolic drug interactions with newer antipsychotics: a comparative review. Basic Clin Pharmacol Toxicol 2007; 100:4–22. doi: 10.1111/j.1742-7843.2007.00017.x

12.

Spina

, Avenoso

, Salemi

. Plasma concentrations of clozapine and its major metabolites during combined treatment with paroxetine or sertraline. Pharmacopsychiatry 2000; 33:213–17. doi: 10.1055/s-2000-8361

13.

Chermá

, Löfgren

, Almkvist

, Hallert

, Bengtsson

. Assessment of the prescription of antidepressant drugs in elderly nursing home patients: a clinical and laboratory follow-up investigation. J Clin Psychopharmacol 2008; 28:424–31. doi: 10.1097/JCP.0b013e31817d79eb

14.

Med Lett Drugs Ther. http://medletter.org/ (accessed 2012 Apr 27).

15.

Karkare

, Bhattacharjee

, Kamble

, Aparasu

. Prevalence and predictors of antidepressant prescribing in nursing home residents in the United States. Am J Geriatr Pharmacother 2011; 9:109–19. doi: 10.1016/j.amjopharm.2011.03.001

16.

Food and Drug Administration. Drugs@FDA database. www.accessdata.fda.gov/scripts/cder/drugsarfda/ (accessed 2011 Jun 7).

17.

Physicians' desk reference 2010. 64th ed. Montvale NJ: Thomson, 2009.

18.

FDA Guideline: drug interaction studies: study design, data analysis, and implications for dosing and labeling. Rockville, MD: Food and Drug Administration, 2006. http://www.fda.gov/downloads/Drugs/GuidanceComplianceRegulatoryInformation/Guidances/ucm072101.pdf (accessed 2012 Feb 10).

19.

Hansten

, Horn

. The top 100 drug interactions, a guide to patient management. Freeland, WA: H & H Publications, LLP; 2010.

20.

Spina

, Santoro

, D'Arrigo

. Clinically relevant pharmacokinetic drug interactions with second-generation antidepressants: an update. Clin Ther 2008; 30:1206–27. doi: 10.1016/S0149-2918(08)80047-1

21.

Landis

, Koch

. The measurement of observer agreement for categorical data. Biometrics 1977; 33:159–74. doi: 102307/2529310

22.

Turpeinen

, Tolonen

, Uusitalo

. Effect of clopidogrel and ticlopidine on cytochrome P450 2B6 activity as measured by bupropion hydroxylation. Clin Pharmacol Ther 2005; 77:553–9. doi: 10.1016/j.clpt.2005.02.010

23.

Farid

, Payne

, Ernest

2nd . Prasugrel, a new thienopyridine antiplatelet drug, weakly inhibits cytochrome P450 2B6 in humans. J Clin Pharmacol 2008; 48:53–9. doi: 10.1177/0091270007309709

24.

Mailing

, Poulsen

, S⊘gaard

. The effect of cimetidine or omeprazole on the pharmacokinetics of escitalopram in healthy subjects. Br J Clin Pharmacol 2005; 60:287–90. doi: 10.1111/j.1365-2125.2005.02423.x

25.

Lobo

, Bergstrom

, Reddy

. In vitro and in vivo evaluations of cytochrome P450 1A2 interactions with duloxetine. Clin Pharmacokinet 2008; 47:191–202. doi: 10.2165/00003088-200847030-00005

26.

Skinner

, Kuan

, Pan

. Duloxetine is both an inhibitor and a substrate of cytochrome P4502D6 in healthy volunteers. Clin Pharmacol Ther 2003; 73:170–7. doi: 10.1067/mcp.2003.28

27.

D'Souza

, Dimmitt

, Robbins

. Effect of alosetron on the pharmacokinetics of fluoxetine. J Clin Pharmacol 2001; 41:455–8. doi: 10.1177/00912700122010177

28.

Gupta

, Banfield

, Kantesaria

, Flannery

, Herron

. Pharmacokinetics/pharmacodynamics of desloratadine and fluoxetine in healthy volunteers. JClin Pharmacol 2004; 44:1252–9. doi: 10.1177/0091270004269518

29.

Sitsen

, Maris

, Timmer

. Concomitant use of mirtazapine and Cimetidine: a drug-drug interaction study in healthy male subjects. Eur J Clin Pharmacol 2000; 56:389–94. doi: 10.1007/s002280000174

30.

Sitsen

, Voortman

, Timmer

. Pharmacokinetics of mirtazapine and lithium in healthy male subjects. J Psychopharmacol 2000; 14:172–6. doi: 10.1177/026988110001400207

31.

Ruwe

FJL

, Smulders

, Kleijn

, Hartmans

HLA

, Sitsen

JMA

. Mirtazapine and paroxetine: a drug-drug interaction study in healthy subjects. Hum Psychopharmacol 2001; 16:449–59. doi: 10.1002/hup.318

32.

Dockens

, Greene

, Barbhaiya

. Assessment of pharmacokinetic and pharmacodynamic drug interactions between nefazodone and digoxin in healthy male volunteers. J Clin Pharmacol 1996; 36:160–7.

33.

Greene

, Salazar

, Dockens

, Kroboth

, Barbhaiya

. Coadministration of nefazodone and benzodiazepines: IV. A pharmacokinetic interaction study with tazepam. J Clin Psychopharmacol 1995; 15:409–16. doi: 10.1097/00004714-199512000-00004

34.

Yasui-Furukori

, Saito

, Inoue

. Terbinafine increases the plasma concentration of paroxetine after a single oral administration of paroxetine in healthy subjects. Eur J Clin Pharmacol 2007; 63:51–6. doi: 10.1007/S00228-006-0217-9

35.

Azzaro

, Ziemniak

, Kemper

, Campbell

, VanDenBerg

. Selegiline transdermal system: an examination of the potential for CYP450-dependent pharmacokinetic interactions with 3 psychotropic medications. J Clin Pharmacol 2007; 47:146–58. doi: 10.1177/0091270006296151

36.

Laine

, Anttila

, Heinonen

. Lack of adverse interactions between concomitantly administered selegiline and citalopram. Clin Neuropharmacol 1997; 20:419–33. doi: 10.1097/00002826-199710000-00006

37.

Kivisto

, Wang

, Backman

. Selegiline pharmacokinetics are unaffected by the CYP3A4 inhibitor itraconazole. Eur J Clin Pharmacol 2001; 57:37–42. doi: 10.1007/s002280100278

38.

Laine

, Anttila

, Helminen

, Karnani

, Huupponen

. Dose linearity study of selegiline pharmacokinetics after oral administration: evidence for strong drug interaction with female sex steroids. Br J Clin Pharmacol 1999; 47:249–54. doi: 10.1046/j.1365–2125.1999.00891.x

39.

Nagy

, Kumar

, Perdomo

. Concurrent administration of donepezil HCl and sertraline HCl in healthy volunteers: assessment of pharmacokinetic changes and safety following single and multiple oral doses. Br J Clin Pharmacol 2004; 58(suppl 1):25–33. doi: 10.1111/j.1365-2125.2004.01801.x

40.

Troy

, Rudolph

, Mayersohn

, Chiang

. The influence of cimetidine on the disposition kinetics of the antidepressant venlafaxine. J Clin Pharmacol 1998; 38:467–74.

41.

Lindh

, Annas

, Meurling

, Dahl

, Al-Shurbaji

. Effect of ketoconazole on venlafaxine plasma concentrations in extensive and poor metabolisers of debrisoquine. Eur J Clin Pharmacol 2003; 59:401–6. doi: 10.1007/s00228-003-0627-x

42.

Hynninen

, Olkkola

, Bertilsson

. Effect of terbinafine and voriconazole on the pharmacokinetics of the antidepressant venlafaxine. Clin Pharmacol Ther 2008; 83:342–8. doi: 10.1038/sj.clpt.6100311

43.

Kubo

, Koue

, Inaba

. Influence of itraconazole co-administration and CYP2D6 genotype on the pharmacokinetics of the new antipsychotic aripiprazole. Drug Metab Pharmacokinet 2005; 20:55–64. doi: 10.2133/dmpk.20.55

44.

Citrome

, Josiassen

, Bark

, Salazar

, Mallikaarjun

. Pharmacokinetics of aripiprazole and concomitant lithium and valproate. J Clin Pharmacol 2005; 45:89–93. doi: 10.1177/0091270004269870

45.

Gossen

, de Suray

, Vandenhende

, Onkelinx

, Gangji

. Influence of fluoxetine on olanzapine pharmacokinetics. AAPS PharmSci 2002; 4:E11. doi: 10.1208/ps040211

46.

Wang

, Zhang

, Li

. The differential effects of steady-state fluvoxamine on the pharmacokinetics of olanzapine and clozapine in healthy volunteers. J Clin Pharmacol 2004; 44:785–92. doi: 10.1177/0091270004266621

47.

Berwaerts

, Cleton

, Herben

. The effects of paroxetine on the pharmacokinetics of paliperidone extended-release tablets. Pharmacopsychiatry 2009; 42:158–63. doi: 10.1055/S-0029-1202265

48.

Thyssen

, Cleton

, Talluri

. No pharmacokinetic interaction between paliperidone extended-release tablets and trimethoprim in healthy subjects. Hum Psychopharmacol 2009; 24:532–9. doi: 10.1002/hup.1049

49.

, Li

, Cheng

. Effect of erythromycin on metabolism of quetiapine in Chinese suffering from schizophrenia. Eur J Clin Pharmacol 2005; 60:791–5. doi: 10.1007/s00228-004-0853-x

50.

Potkin

, Thyrum

, Alva

. The safety and pharmacokinetics of quetiapine when coadministered with haloperidol, risperidone, or thioridazine. J Clin Psychopharmacol 2002; 22:121–30. doi: 10.1097/00004714-200204000-00004

51.

Grimm

, Richtand

, Winter

, Stams

, Reele

. Effects of cytochrome P450 3A modulators ketoconazole and carbamazepine on quetiapine pharmacokinetics. Br J Clin Pharmacol 2006; 61:58–69. doi: 10.1111/j.1365–2125.2005.02507.x

52.

Reyes

, Preskorn

, Khan

. Concurrent administration of donepezil HCl and risperidone in patients with schizophrenia: assessment of pharmacokinetic changes and safety following multiple oral doses. Br J Clin Pharmacol 2004; 58 (suppl 1):50–7. doi: 10.1111/j.1365-2125.2004.01817.x

53.

Amchin

, Zarycranski

, Taylor

, Albano

, Klockowski

. Effect of venlafaxine on the pharmacokinetics of risperidone. J Clin Pharmacol 1999; 39:297–309.

54.

Wilner

, Hansen

, Folger

, Geoffroy

. The pharmacokinetics of ziprasidone in healthy volunteers treated with cimetidine or antacid. Br J Clin Pharmacol 2000; 49 (suppl 1):57S–60S. doi: 10.1046/j.1365-2125.2000.00154.x

55.

Miceli

, Smith

, Robarge

, Morse

, Laurent

. The effects of ketoconazole on ziprasidone pharmacokinetics—a placebo-controlled crossover study in healthy volunteers. Br J Clin Pharmacol 2000; 49 (suppl 1): 71S–6S. doi: 10.1046/j.1365-2125.2000.00156.x

56.

Sanchez Garcia

, Carcas

, Zapater

. Absence of an interaction between ibuprofen and zaleplon. Am J Health Syst Pharm 2000; 57:1137–41.

57.

Greenblatt

, von Moltke

, Harmatz

. Kinetic and dynamic interaction study of zolpidem with ketoconazole, itraconazole, and fluconazole. Clin Pharmacol Ther 1998; 64:661–71. doi: 10.1208/ps040211

58.

Allard

, Sainati

, Roth-Schechter

, MacIntyre

. Minimal interaction between fluoxetine and multiple-dose Zolpidem in healthy women. Drug Metab Dispos 1998; 26:617–22.

59.

Piergies

, Sweet

, Johnson

, Roth-Schechter

, Allard

. The effect of co-administration of Zolpidem with fluoxetine: pharmacokinetics and pharmacodynamics. Int J Clin Pharmacol Ther 1996; 34:178–83.

60.

Hulhoven

, Desager

, Harvengt

. Lack of interaction between zolpidem and H₂ antagonists, cimetidine and ranitidine. Int. J Clin Pharmacol Res 1988; 8:471–76.

61.

Luurila

, Kivistö

, Neuvonen

. Effect of itraconazole on the pharmacokinetics and pharmacodynamics of zolpidem. Eur J Clin Pharmacol 1998; 54:163–6. doi: 10.1007/s002280050439

62.

Saari

, Laine

, Leino

. Effect of voriconazole on the pharmacokinetics and pharmacodynamics of zolpidem in healthy subjects. Br J Clin Pharmacol 2007; 63:116–20. doi: 10.1111/j.1365-21252006.02707.x

63.

Product information. Celexa tablet/solution (Citalopram). St. Louis, MO: Forest Pharmaceuticals, February 2009.

64.

Product information. Pristiq (desvenlafaxine) tablet, extended release for oral use. St. Louis, MO: Forest Pharmaceuticals, January 2009.

65.

Product information. Cymbalta (duloxetine) capsule, delayed release. Indianapolis, IN: Eli Lilly and Company, January 2010.

66.

Product information. Lexapro (escitalopram) tablets/oral solution. St. Louis, MO: Forest Pharmaceuticals, March 2009.

67.

Product information. Nefazodone tablet. North Wales, PA: Teva Pharmaceuticals USA, August 2010.

68.

Product information. Emsam (selegiline) patch. Napa, CA: Dey Pharma, LP. August 2009.

69.

Product information. Sertraline tablet, film coated. Morgantown, WV: Mylan Pharmaceuticals, April 2010.

70.

Product information. Effexor XR (venlafaxine) extended-release capsules. Madison, NJ: Wyeth, June 2009.

71.

Product information. Abilify (aripiprazole) tablet/solution/injection, solution. Rockville, MD: Otsuka America Pharmaceuticals, November 2009.

72.

Product information. Saphris (asenapine) sublingual tablets. Roseland, NJ: Organon Pharmaceuticals USA, August 2009.

73.

Product information. Fanapt (iloperidone) tablets. Rockville, MD: Vanda Pharmaceuticals, May 2009.

74.

Product information. Zyprexa (olanzapine) tablet. Indianapolis, IN: Eli Lilly and Company, January 2010.

75.

Product information. Invega (paliperidone) tablet, extended release. Titusville, NJ: Ortho-McNeil-Janssen Pharmaceuticals, January 2010.

76.

Product information. Seroquel (quetiapine). London, England: AstraZeneca, January 2009.

77.

Product information. Geodon (ziprasidone) capsules/injection. New York, NY: Pfizer, June 2009.

78.

Product information. Lunesta (eszopiclone) tablet, coated. Marlborough, MA: Sepracor Inc., June 2010.

79.

Product information. Rozerem (ramelteon) tablet, film coated. Deerfield, IL: Takeda Pharmaceuticals North America, Inc, October 2008.

80.

Product information. Zaleplon capsule. North Wales, PA: Teva Pharmaceuticals USA, June 2008.

81.

Product information. Ambien CR (Zolpidem) extended-release tablets. Bridgewater, NJ,: Sanofi-aventis US, 2008.

82.

Kustra

, Corrigan

, Dunn

, Duncan

, Hsyu

. Lack of effect of Cimetidine on the pharmacokinetics of sustained-release bupropion. J Clin Pharmacol 1999; 39:1184–8.

83.

Ketter

. Carbamazepine but not valproate induces bupropion metabolism. J Clin Psychopharmacol 1995; 15:327–33. doi: 10.1097/00004714-199510000-00004

84.

Larsen

, Priskorn

, Over⊘

. Lack of Citalopram effect on oral digoxin pharmacokinetics. J Clin Pharmacol 2001; 41:340–6. doi: 10.1177/00912700122010041

85.

Gram

, Hansen

, Sindrup

. Citalopram: interaction studies with levomepromazine, imipramine, and lithium. Ther Drug Monit 1993; 15:18–24. doi: 10.1097/00007691-199302000-00003

86.

Gutierrez

, Abramowitz

. Lack of effect of a single dose of ketoconazole on the pharmacokinetics of Citalopram. Pharmacotherapy 2001; 21: 163–8. doi: 10.1592/phco.21.2.163.34101

87.

Baumann

, Nil

, Souche

. A double-blind, placebo-controlled study of citalopram with and without lithium in the treatment of therapy-resistant depressive patients: a clinical, pharmacokinetic, and pharmacogenetic investigation. J Clin Psychopharmacol 1996; 16:307–14. doi: 10.1097/00004714-199608000-00006

88.

Nolting

, Abramowitz

. Lack of interaction between citalopram and the CYP3A4 substrate triazolam. Pharmacotherapy 2000; 20:750–5. doi: 10.1592/phco.20.9.750.35198

89.

Barbhaiya

, Shukla

, Greene

, Breul

, Midha

. Investigation of pharmacokinetic and pharmacodynamic interactions after coadministration of nefazodone and haloperidol. J Clin Psychopharmacol 1996; 16:26–34. doi: 10.1097/00004714-199602000-00005

90.

Barbhaiya

, Shukla

, Greene

. Lack of interaction between nefazodone and cimetidine: a steady state pharmacokinetic study in humans. Br J Clin Pharmacol 1995; 40:161–5.

91.

Khan

, Preskorn

, Horst

. Coadministration of nefazodone and desipramine: a pharmacokinetic interaction study. J Pak Med Assoc 2007; 57: 230–5.

92.

Salazar

, Marathe

, Fulmor

, Lee

, Raymond

, Uderman

. Pharmacokinetic and pharmacodynamic evaluation during coadministration of nefazodone and propranolol in healthy men. J Clin Pharmacol 1995; 35:1109–18.

93.

Troy

, Parker

, Hicks

, Boudino

, Chiang

. Pharmacokinetic interaction between multiple-dose venlafaxine and single-dose lithium. J Clin Pharmacol 1996; 36:175–81.

94.

Product information. Clozapine tablet. Morgantown, WV: Mylan Pharmaceuticals, December 2009.

95.

Potkin

, Thyrum

, Alva

. Effect of fluoxetine and imipramine on the pharmacokinetics and tolerability of the antipsychotic quetiapine. J Clin Psychopharmacol 2002; 22:174–82. doi: 10.1097/00004714-200204000-00011

96.

Product information. Wellbutrin (bupropion) tablet, film coated. London, England: SmithKline Beecham, August 2009.

97.

Product information. Remeron soltab (mirtazapine) orally disintegrating tablets once-a-day. Kenilworth, NJ: Schering-Plough, March 2009.

98.

Product information. Paxil (paroxetine) tablet, film coated. London, England: SmithKline Beecham, June 2010.

99.

Product information. Risperdal (risperidone) tablets/oral solution. Titusville, NJ: Janssen Pharmaceuticals, Inc., April 2010.

100.

, Malone

, Skrepnek

. Prescribers' knowledge of and sources of information for potential drug-drug interactions: a postal survey of US prescribers. Drug Saf 2008; 31:525–36. doi: 102165/00002018-200831060-00007

101.

Chao

, Maibach

. Lack of drug interaction conformity in commonly used drug compendia for selected at-risk dermatologic drugs. Am J Clin Dermatol 2005; 6:105–11. doi: 10.2165/00128071-200506020-00005

102.

Anthony

, Romero

, Malone

. Warfarin interactions with substances listed in drug information compendia and in the FDA-approved label for warfarin sodium. Clin Pharmacol Ther 2009; 86:425–9. doi: 10.1038/clpt.2009.95

103.

Fulda

, Valuck

, Zanden

. Disagreement among drug compendia on inclusion and ratings of drug-drug interactions. Curr Ther Res Clin Exp 2000; 61:540–8. doi:16/S0011-393X(00)80036-3

104.

Wang

, Wong

, Lightwood

, Cheng

. Black box warning contraindicated comedications: concordance among three major drug interaction screening programs. Ann Pharmacother 2010; 44:28–34. doi: 10.1345/aph.1M475

105.

Abarca

, Malone

, Armstrong

. Concordance of severity ratings provided in four drug interaction compendia. J Am Pharm Assoc 2004; 44:136–41. doi: 10.1331/154434504773062582

106.

Olvey

, Clauschee

, Malone

. Comparison of critical drug-drug interaction listings: the Department of Veterans Affairs medical system and standard reference compendia. Clin Pharmacol Ther 2010; 87:48–51. doi: 10.1038/clpt.2009.198

107.

Wong

, Ko

, Chan

. Clinically significant drug-drug interactions between oral anticancer agents and nonanticancer agents: profiling and comparison of two drug compendia. Ann Pharmacother 2008; 42:1737–48. doi: 10.1345/aph.1L255

108.

Vitry

. Comparative assessment of four drug interaction compendia. Br J Clin Pharmacol 2007; 63:709–14. doi: 10.1111/j.1365–2125.2006.02809.x

109.

FDA Guideline. In vivo drug metabolism/drug interaction studies-study design, data analysis, and implications for dosing and labeling. Rockville, MD: Food and Drug Administration, 1999. http://www.fda.gov/downloads/Drugs/GuidanceComplianceRegulatoryInformation/Guidances/ucm072119.pdf (accessed 2012 Feb 10).